Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.56 |
| ▸ | HSD17B10 | Q99714 | 5/20 | 0.56 |
| ▸ | GAA | P10253 | 3/20 | 0.56 |
| ▸ | HPGD | P15428 | 3/20 | 0.56 |
| ▸ | NPC1 | O15118 | 2/20 | 0.56 |
| ▸ | GLA | P06280 | 1/20 | 0.56 |
| ▸ | CASP1 | P29466 | 1/20 | 0.56 |
| ▸ | CASP7 | P55210 | 1/20 | 0.56 |
| ▸ | NPSR1 | Q6W5P4 | 5/20 | 0.54 |
| ▸ | MAPT | P10636 | 1/20 | 0.54 |
| ▸ | RAB9A | P51151 | 1/20 | 0.54 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | CDK4 | P11802 | 1/20 | 0.49 |
| ▸ | CDK2 | P24941 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | CRHBP | P24387 | 1/20 | 0.47 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26359012 | 0.81 | ALDH1A1 (0.54) | KMT2AKDM4EALDH1A1HSD17B10GAA | |
| SCHEMBL15004608 | 0.81 | KMT2A (0.61) | KMT2AKDM4EALDH1A1HSD17B10GAA | |
| SCHEMBL6479532 | 0.79 | KMT2A (0.54) | KMT2AKDM4EALDH1A1HSD17B10GAA | |
| SCHEMBL7965109 | 0.79 | KMT2A (0.54) | KMT2AKDM4EALDH1A1HSD17B10GAA | |
| SCHEMBL14685183 | 0.79 | KDM4E (0.56) | KMT2AKDM4EALDH1A1HSD17B10GAA | |
| SCHEMBL15004600 | 0.79 | NPC1 (0.58) | KMT2AKDM4EALDH1A1HSD17B10GAA | |
| SCHEMBL18901345 | 0.79 | KMT2A (0.54) | KMT2AKDM4EALDH1A1HSD17B10GAA | |
| SCHEMBL8829992 | 0.79 | ALDH1A1 (0.52) | KMT2AKDM4EALDH1A1HSD17B10GAA | |
| SCHEMBL792006 | 0.79 | KMT2A (0.59) | KMT2AKDM4EALDH1A1HSD17B10GAA | |
| SCHEMBL25889552 | 0.79 | ALDH1A1 (0.52) | KMT2AKDM4EALDH1A1HSD17B10GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 262 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250243194-A1 | ANTAGONIST OF ADENOSINE RECEPTORS | JANSSEN PHARMACEUTICA NV (BE) | 2025-07-31 | — | — | US | disclosed |
| US-20240208952-A1 | THIOPHENE GLP-1 RECEPTOR AGONIST AND USE THEREOF | HANGZHOU ZHONGMEIHUADONG PHARMACEUTICAL CO., LTD. (CN) | 2024-06-27 | — | — | US | disclosed |
| US-20240208952-A1 | THIOPHENE GLP-1 RECEPTOR AGONIST AND USE THEREOF | HANGZHOU ZHONGMEIHUADONG PHARMACEUTICAL CO., LTD. (CN) | 2024-06-27 | — | — | US | disclosed |
| US-20240018175-A1 | ORGANOMETALLIC COMPOUND, LIGHT-EMITTING DEVICE INCLUDING THE SAME, AND ELECTRONIC APPARATUS AND ELECTRONIC EQUIPMENT INCLUDING THE LIGHT-EMITTING DEVICE | SAMSUNG DISPLAY CO., LTD. (KR) | 2024-01-18 | — | — | US | disclosed |
| US-20240018175-A1 | ORGANOMETALLIC COMPOUND, LIGHT-EMITTING DEVICE INCLUDING THE SAME, AND ELECTRONIC APPARATUS AND ELECTRONIC EQUIPMENT INCLUDING THE LIGHT-EMITTING DEVICE | SAMSUNG DISPLAY CO., LTD. (KR) | 2024-01-18 | — | — | US | disclosed |
| US-20230406808-A1 | DEHYDRATION OF LACTIC ACID AND RELATED COMPOUNDS IN SOLID ACIDS VIA MULTIFUNCTIONAL FLEXIBLE MODIFIERS | NATIONAL SCIENCE FOUNDATION | 2023-12-21 | — | — | US | disclosed |
| US-20230329103-A1 | LIGHT-EMITTING DEVICE AND ELECTRONIC APPARATUS INCLUDING THE SAME | SAMSUNG DISPLAY CO., LTD. (KR) | 2023-10-12 | — | — | US | disclosed |
| US-11744146-B2 | Amine-based compound and organic light-emitting device including the same | SAMSUNG DISPLAY CO., LTD. (KR) | 2023-08-29 | — | — | US | disclosed |
| EP-3675847-B1 | SPIROCYCLE COMPOUNDS AND METHODS OF MAKING AND USING SAME | H LUNDBECK AS (DK) | 2023-07-12 | — | — | EP | disclosed |
| US-11696499-B2 | Organic light-emitting device | SAMSUNG DISPLAY CO., LTD. (KR) | 2023-07-04 | — | — | US | disclosed |
| US-20040116399-A1 | Inhibitors of factor Xa | MILLENNIUM PHARMACEUTICALS, INC. | 2004-06-17 | — | — | US | disclosed |
| US-6720329-B2 | ANTIINFLAMMATORY AGENTS | BRISTOL-MYERS SQUIBB PHARMA | 2004-04-13 | — | — | US | disclosed |
| EP-1373199-A4 | SPIRO-CYCLIC BETA-AMINO ACID DERIVATIVES AS INHIBITORS OF MATRIX METALLOPROTEINASES AND TNF-ALPHA CONVERTING ENZYME (TAGE) | BRISTOL MYERS SQUIBB PHARMA CO (US) | 2004-04-07 | — | — | EP | disclosed |
| US-20040039013-A1 | Process for preparing a substituted imidazopyridine compound | ASTRAZENECA AB (SE) | 2004-02-26 | — | — | US | disclosed |
| EP-1373199-A2 | SPIRO-CYCLIC BETA-AMINO ACID DERIVATIVES AS INHIBITORS OF MATRIX METALLOPROTEINASES AND TNF-ALPHA CONVERTING ENZYME (TAGE) | Bristol-Myers Squibb Pharma Company (US) | 2004-01-02 | — | — | EP | disclosed |
| EP-1317455-A1 | PROCESS FOR PREPARING A SUBSTITUTED IMIDAZOPYRIDINE COMPOUND | AstraZeneca AB (SE) | 2003-06-11 | — | — | EP | disclosed |
| WO-2002074738-A2 | SPIRO-CYCLIC BETA-AMINO ACID DERIVATIVES AS INHIBITORS OF MATRIX METALLOPROTEINASES AND TNF-ALPHA CONVERTING ENZYME (TAGE) | BRISTOL-MYERS SQUIBB COMPANY (US) | 2002-09-26 | — | — | WO | disclosed |
| WO-2002020523-A1 | PROCESS FOR PREPARING A SUBSTITUTED IMIDAZOPYRIDINE COMPOUND | ASTRAZENECA AB (SE) | 2002-03-14 | — | — | WO | disclosed |
| EP-0841904-A1 | ORAL PHARMACEUTICAL COMPOSITIONS WITH DELAYED RELEASE OF REVERSIBLE PROTON PUMP INHIBITORS | Byk Gulden Lomberg Chemische Fabrik GmbH (DE) | 1998-05-20 | — | — | EP | disclosed |
| WO-1997002021-A1 | ORAL PHARMACEUTICAL COMPOSITIONS WITH DELAYED RELEASE OF REVERSIBLE PROTON PUMP INHIBITORS | BYK GULDEN LOMBERG CHEMISCHE FABRIK GMBH (DE) | 1997-01-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240018175-A1 | ORGANOMETALLIC COMPOUND, LIGHT-EMITTING DEVICE INCLUDING THE SAME, AND ELECTRONIC APPARATUS AND ELECTRONIC EQUIPMENT INCLUDING THE LIGHT-EMITTING DEVICE | GPX1, LAGE3, NFE2L2 | KMT2A 119/4885KDM4E 913/4885ALDH1A1 17/4885 |
| US-20040039013-A1 | Process for preparing a substituted imidazopyridine compound | CYP1B1, BRD1, SKP1 | KMT2A 2103/4885KDM4E 1571/4885ALDH1A1 456/4885 |
| US-20250243194-A1 | ANTAGONIST OF ADENOSINE RECEPTORS | ADORA2B, ADORA2A, ADORA1 | KMT2A 2476/4885KDM4E 3478/4885ALDH1A1 637/4885 |
| US-11744146-B2 | Amine-based compound and organic light-emitting device including the same | AOC2, AOC1, EML4 | KMT2A 149/4885KDM4E 655/4885ALDH1A1 76/4885 |
| US-20240208952-A1 | THIOPHENE GLP-1 RECEPTOR AGONIST AND USE THEREOF | GLP1R, GIPR, GCGR | KMT2A 4321/4885KDM4E 2930/4885ALDH1A1 2375/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.